Gene Therapy for Spinal Muscular Atrophy in 2026: Lessons from the Frontlines

Introduction

The Treatment Landscape Has Evolved, but the Underlying Biology Remains Unchanged

By 2026, gene transfer for 5q SMA is no longer a single-product story. ZOLGENSMA (onasemnogene abeparvovec-xioi) is an intravenous AAV9-based therapy approved in the United States for pediatric patients younger than 2 years with bi-allelic SMN1 mutations. ITVISMA (onasemnogene abeparvovec-brve) is an intrathecal AAV9-based therapy approved for adults and children age 2 years and older with a confirmed SMN1 mutation. Both deliver a functional SMN transgene. However, neither edits the patient’s defective gene, restores motor neurons that have already been lost, or removes the need for future SMA care.[1,2]

That distinction explains nearly every practical lesson from high-volume SMA programs. The treatment can be transformative, especially before symptoms emerge, but the ceiling for recovery is constrained by the amount of irreversible denervation present at dosing. Current best-practice recommendations therefore emphasize treatment as early as possible, individualized goal setting, objective response measurement, and continuing multidisciplinary care.[3]

Comparing the Current U.S. Onasemnogene Treatment Options

Feature	ZOLGENSMA	ITVISMA
Labeled population	Pediatric patients younger than 2 years with SMA and bi-allelic SMN1 mutations.	Adults and pediatric patients age 2 years and older with a confirmed SMN1 mutation.
Route and dose	Single IV infusion, 1.1 x 10^14 vector genomes/kg over 60 minutes.	Single intrathecal injection, fixed 1.2 x 10^14 vector genomes in 3 mL over about 1 to 2 minutes.
Prior gene therapy	Repeat administration has not been evaluated.	Patients previously treated with ZOLGENSMA should not receive ITVISMA; do not re-administer ITVISMA.
Core pre-dose checks	Clinical stability, no active infection, liver assessment, creatinine, CBC with platelets, anti-AAV9 antibodies.	Clinical stability including respiratory status, no active or recent infection, liver assessment, creatinine, CBC with platelets, anti-AAV9 antibodies, lumbar-puncture readiness.
Major safety focus	Serious liver injury and acute liver failure, thrombocytopenia, TMA, troponin elevation, systemic immune response, infusion reactions.	Serious liver injury, thrombocytopenia, peripheral sensory neuropathy, TMA, troponin elevation, procedural risks.

Frontline Lesson 1: Early Treatment Timing Sets the Upper Limit of Motor Recovery

The clearest efficacy gradient in the onasemnogene program is not between brands or routes. It is between treatment before substantial motor-neuron loss and treatment after established weakness. The early START study showed that a single intravenous dose could change survival and motor trajectories in symptomatic infants, and the subsequent STR1VE trials reproduced clinically meaningful survival and milestone gains in larger infant cohorts.[4,5,6]

The presymptomatic SPR1NT cohorts made the timing effect more visible. Among 14 infants with two SMN2 copies, all sat independently for at least 30 seconds by 18 months, and 11 achieved sitting within the expected developmental window. In the three-copy cohort, 14 of 15 walked independently and the remaining child stood independently. These were small, selected, nonrandomized cohorts, but the direction of effect is consistent with the biology of irreversible motor-neuron loss.[7,8]

For clinicians, this changes the operational priority. A positive newborn screen is not a routine referral. It is a time-sensitive care transition that requires rapid confirmatory testing, SMN2 copy-number characterization, treatment counseling, payer and logistics coordination, and baseline safety work in parallel rather than in sequence. A delay that seems administratively modest can consume a meaningful fraction of an infant’s remaining motor-neuron reserve.[3,7,8]

A Summary of the Clinical Evidence Across Different Patient Populations

Clinical setting	Key evidence	Practical interpretation
Symptomatic infantile-onset SMA	STR1VE-US: 13 of 22 sat independently for at least 30 seconds at 18 months; 20 of 22 were alive without permanent ventilation at 14 months. STR1VE-EU: 14 of 32 sat independently for at least 10 seconds by 18 months.	IV gene transfer can markedly alter the expected course, but response is heterogeneous and the trials were single-arm with historical comparison.
Presymptomatic infants with two SMN2 copies	SPR1NT: all 14 sat independently for at least 30 seconds; 11 did so within the normal developmental window.	Treatment before symptoms offers the highest observed motor ceiling.
Presymptomatic infants with three SMN2 copies	SPR1NT: 14 of 15 walked independently; the remaining child stood independently.	A favorable early outcome does not eliminate the need for long-term developmental and neuromuscular surveillance.
Children age 2 to younger than 18 years, treatment-naive sitters	STEER: least-squares mean HFMSE difference of 1.88 points versus sham at 52 weeks, 95% CI 0.51 to 3.25; P=0.0074.	The average randomized effect was statistically significant but modest; individual expectations should remain phenotype-specific.
Long-term START follow-up	At up to roughly 10 years, all 13 followed participants were alive and 12 of 13 were free of permanent ventilation; most had later received another SMA therapy.	Durability is encouraging, but the cohort is very small and add-on therapy limits attribution to the original dose alone.

Frontline Lesson 2: Route Selection Is Driven by Clinical Indication Rather Than Preference

The current U.S. labels largely divide onasemnogene use by age. A child younger than 2 years may meet the ZOLGENSMA indication, while a patient age 2 years or older may meet the ITVISMA indication. The formulations, doses, routes, and evidence bases are not interchangeable. A center should document the exact genetic diagnosis, age on the planned treatment date, prior SMA therapies, and whether any prior onasemnogene product was given before beginning authorization or scheduling.[1,2]

For ITVISMA, the label is explicit that patients previously treated with ZOLGENSMA should not be treated with ITVISMA. ITVISMA is also a lumbar-puncture procedure that should be performed by an experienced professional. Spinal anatomy, respiratory reserve, positioning tolerance, the potential need for imaging guidance or sedation, and the center’s post-procedure protocol are therefore part of candidacy, not last-minute technical details.[2]

The anti-AAV9 discussion also requires precision. Both labels call for baseline anti-AAV9 antibody testing. ZOLGENSMA clinical experience was established in patients with titers at or below the studied threshold, with retesting permitted when the result is above 1:50. ITVISMA pivotal studies required baseline titers below 1:50, but the label does not create a simple universal cutoff that can be applied without regard to the current assay and product-specific instructions. Centers should use the current label, validated laboratory method, and treatment-program protocol rather than relying on a remembered historical threshold.[1,2]

Frontline Lesson 3: A One-Time Dose Requires a Months-Long Safety Surveillance Program

The phrase “one-time therapy” can unintentionally minimize the clinical workload after dosing. Both products require systemic corticosteroids beginning one day before treatment, generally at a prednisolone-equivalent dose of 1 mg/kg/day for 30 days. If the clinical examination and liver tests are unremarkable, the dose is tapered gradually over the next 28 days. Persistent abnormalities can require a longer course, a higher dose, intravenous therapy, or hepatology input. Corticosteroids should not be stopped abruptly.[1,2,16]

Hepatic surveillance is the center of the program. Baseline assessment includes a clinical liver evaluation and laboratory testing. After either product, AST, ALT, and total bilirubin are checked weekly through the first month and during the corticosteroid taper, then every other week for another month if the patient is clinically stable with unremarkable findings. Liver function must be monitored for at least three months and longer when clinically indicated. For ZOLGENSMA, the label also specifies coagulation-related baseline and follow-up elements and a prompt pediatric gastroenterology or hepatology consultation when abnormalities persist.[1,2]

Real-world series confirm why this cannot be treated as a clerical lab schedule. In a 76-patient observational cohort, corticosteroid treatment was often prolonged because of liver-enzyme elevation. Postmarketing experience has also documented acute serious liver injury and acute liver failure, including fatal cases with intravenous therapy, which is why the ZOLGENSMA label carries a boxed warning for serious liver injury and acute liver failure and ITVISMA carries a boxed warning for serious liver injury.[1,2,13,16,17]

A Practical Safety Surveillance Framework for Post-Dose Monitoring

Signal	What to monitor	Frontline response
Hepatotoxicity	Symptoms such as vomiting, jaundice, or clinical deterioration; AST, ALT, bilirubin, and applicable synthetic-function tests.	Do not taper steroids until label-defined liver criteria are met. Escalate monitoring and involve gastroenterology or hepatology promptly when abnormalities worsen or persist.
Thrombocytopenia	CBC and platelets. ZOLGENSMA: at least weekly for month 1, then every other week in months 2 and 3 until baseline. ITVISMA: at least weekly for month 1 and thereafter as clinically indicated until baseline.	Repeat urgently for unexpected bruising or bleeding and evaluate the full clinical context rather than treating an isolated count.
Thrombotic microangiopathy	Hypertension, easy bruising, seizures, reduced urine output, thrombocytopenia, hemolysis, and acute kidney injury. Events after IV therapy have often occurred within the first 2 weeks.	Obtain urgent hematologic and renal evaluation. Involve hematology and nephrology immediately when TMA is suspected.
Cardiac injury	Troponin I trends and clinical cardiac findings according to the applicable label and center protocol.	Consider cardiac evaluation after treatment and consult cardiology when indicated.
Peripheral sensory neuropathy	After ITVISMA, new numbness, tingling, prickling, or pain in the limbs, with onset observed around 3 weeks in trials.	Perform a neurologic evaluation and direct testing or symptom management to the presentation.
Infusion or procedure complications	IV infusion reaction signs for ZOLGENSMA; lumbar-puncture, sedation, positioning, and post-procedure issues for ITVISMA.	Use product-specific emergency and procedural protocols; do not collapse both routes into one generic gene-therapy order set.

Frontline Lesson 4: Clinical Stability Is an Absolute Prerequisite for Treatment

A child with an intercurrent respiratory infection, poor hydration, nutritional instability, or worsening respiratory status may be at greater risk when AAV exposure, immune activation, and corticosteroids are layered onto the acute illness. Both labels direct clinicians to treat only when the patient is clinically stable and to postpone treatment when infection is active. The ITVISMA label specifically includes active or recent infection and respiratory status in the readiness assessment. Vaccination and seasonally appropriate respiratory prophylaxis should be coordinated before treatment according to the applicable product label and local protocol.[1,2]

This creates a narrow operational balance. Waiting for a clinically unstable patient to recover is appropriate, but allowing preventable administrative delays after recovery is not. High-functioning programs often manage laboratory testing, vaccine review, steroid dispensing, respiratory planning, procedure or infusion scheduling, and caregiver education with a single readiness checklist and one accountable coordinator.[15,18]

Comprehensive Pre-Dose Readiness Checklist for Clinical Teams

• Confirm 5q SMA genetically and record the exact SMN1 finding and SMN2 copy number when available.
• Confirm the product-specific age indication on the planned dosing date and document all prior disease-modifying therapy, especially any prior onasemnogene exposure.
• Define baseline motor function with an age- and phenotype-appropriate instrument, plus respiratory, bulbar, nutritional, orthopedic, and developmental status.
• Verify clinical stability, including hydration, nutrition, infection status, and respiratory status. Resolve active infection before dosing.
• Complete product-specific baseline liver testing, creatinine, CBC with hemoglobin and platelets, and anti-AAV9 antibody testing.
• Coordinate vaccination and respiratory-virus prophylaxis with the corticosteroid schedule and current label.
• For ITVISMA, confirm lumbar-puncture feasibility, procedural expertise, imaging or sedation needs, positioning tolerance, and post-procedure monitoring.
• Dispense and teach the corticosteroid plan before treatment. Give caregivers a written lab calendar and urgent symptom list.
• Preassign hepatology, hematology, nephrology, cardiology, respiratory, and emergency escalation pathways rather than improvising them after an abnormal result.

Frontline Lesson 5: Interpreting the ITVISMA Clinical Trial Evidence With Precision

STEER was a randomized, double-blind, sham-controlled trial in treatment-naive participants age 2 to younger than 18 years who could sit but had never walked independently. At 52 weeks, the least-squares mean HFMSE change was 2.39 points with intrathecal onasemnogene and 0.51 points with sham, a between-group difference of 1.88 points. The result was statistically significant, but none of the five prespecified secondary efficacy endpoints met the multiplicity-controlled threshold, even though all numerically favored treatment.[10,11]

That is a positive trial, but it should not be oversold. A group-average HFMSE advantage does not predict the magnitude of benefit for a specific child, adolescent, or adult. There was no head-to-head comparison with nusinersen or risdiplam, and the trial population did not include adults. The adult indication was extended beyond the pivotal pediatric age range through FDA regulatory extrapolation based on the SMA disease continuum, subgroup findings, mechanism, and related evidence. The FDA review also noted that chronic adult comorbidities may increase concern for hepatotoxicity or cardiotoxicity.[10,11]

For treatment-experienced patients, STRENGTH adds useful but limited information. It enrolled 27 participants age 2.4 to 17.7 years who had previously received nusinersen or risdiplam. The single-arm study found no deaths or treatment discontinuations due to adverse events, but transient thrombocytopenia, hepatotoxicity, and possible sensory symptoms occurred. Because the study was small and lacked a concurrent comparator, it cannot establish that switching is better than continuing a prior therapy or define a universal washout interval.[12]

Frontline Lesson 6: Gene Therapy Alters the Trajectory but Does Not End SMA Care

Families may understandably hear a one-time gene therapy as a one-time solution. The more accurate expectation is a changed disease trajectory with an uncertain residual phenotype. Earlier treatment can preserve more function, but patients may still have weakness, fatigability, contractures, scoliosis, hip instability, dysphagia, growth problems, sleep-disordered breathing, ineffective cough, recurrent infection, and developmental or participation needs.[3,14,19,20]

The French real-world monotherapy cohort illustrates this gap between motor improvement and cure language. Children gained function, yet residual respiratory and feeding support remained necessary for some, and spinal deformity and bracing were common during follow-up. The message is not that gene therapy failed. It is that survival and motor gains reveal a longer, evolving phenotype that still requires anticipatory care.[14]

Essential Domains That Must Continue to Be Measured in Lifelong Follow-Up

Domain	Examples of ongoing assessment	Why it matters after gene therapy
Motor and participation	CHOP INTEND, HFMSE, RULM, timed function when appropriate, fatigue, school and daily participation.	A single motor score can miss meaningful gains, plateau, new weakness, or burdens important to the patient.
Respiratory	Sleep and ventilation review, cough effectiveness, airway-clearance needs, infection plan.	Improved motor function does not guarantee normal bulbar or respiratory reserve.
Swallowing and nutrition	Feeding safety, growth, hydration, constipation, aspiration risk, gastrostomy needs.	Nutrition and respiratory health are tightly linked, especially during illness and corticosteroid exposure.
Orthopedic and rehabilitation	Range of motion, contractures, hip and spine surveillance, seating, bracing, equipment, activity plan.	Longer survival and altered motor trajectories create new orthopedic and rehabilitation needs.
Development and psychosocial health	Communication, cognition, behavior, caregiver burden, access, transition planning.	Treatment success includes function, participation, family sustainability, and adult care transition, not only a motor-scale change.

Long-Term Durability Is Encouraging, but the Evidence Is Not Yet Settled

Long-term follow-up of the original START cohort now extends to approximately a decade for some participants. In the 2026 interim analysis, all 13 followed participants were alive, and 12 were free of permanent ventilation. That is important reassurance that benefit can persist well beyond the first years after dosing.[9]

The same study also shows why durability must be described carefully. The sample is extremely small, there is no concurrent control group, and most participants later received nusinersen or risdiplam. Long-term outcome therefore reflects the original gene transfer plus supportive care, survival bias, and often subsequent disease-modifying therapy. For ITVISMA, FDA-required long-term follow-up is ongoing. Both labels also retain a theoretical tumorigenicity warning related to possible AAV vector integration, so long-term surveillance is part of the treatment contract.[1,2,9,11]

Navigating Treatment Sequencing and Combination Therapy Where Evidence Remains Limited

SMA clinics increasingly see patients who have already received another disease-modifying therapy, have had a partial response, or have changing goals with age. These are legitimate clinical problems, but the evidence does not support a simple rule that more mechanisms always produce more benefit. Objective baseline measures, a clearly defined treatment goal, burden and risk, and a planned reassessment interval are essential.[3,15]

Three boundaries are especially important. First, prior ZOLGENSMA excludes ITVISMA under the current label. Second, STRENGTH supports the feasibility of intrathecal treatment after prior nusinersen or risdiplam in a small pediatric cohort, but it does not prove comparative advantage or define a universal sequencing schedule. Third, repeat administration of either onasemnogene product is not established. Combination or add-on decisions involving other SMA therapies should therefore be individualized in an SMA specialty center and described as an evidence gap, not a routine standard.[1,2,3,12,15]

A Practical Step-by-Step Clinical Algorithm for SMA Gene Therapy Management

• Identify the treatment window. For a newborn-screened infant, accelerate confirmatory testing and counseling. For an older patient, define whether the goal is improvement, stabilization, preservation of a specific function, or reduction in treatment burden.
• Match the patient to the current U.S. indication. Confirm age, SMN1 result, prior onasemnogene exposure, and route feasibility before starting authorization.
• Establish a multidomain baseline. Record motor, respiratory, bulbar, nutritional, orthopedic, developmental, and patient-reported priorities.
• Complete clinical and laboratory readiness in parallel. Do not dose through active infection or instability, but do not allow preventable administrative delay after stability is restored.
• Execute the product-specific steroid, infusion or procedure, and monitoring protocol exactly. Use separate order sets for ZOLGENSMA and ITVISMA.
• Treat abnormal tests as clinical signals. Escalate liver, platelet, renal, cardiac, or neurologic findings using preassigned specialty pathways.
• Continue SMA care after the gene-therapy episode. Reassess outcomes at planned intervals and revisit goals without assuming that a plateau equals failure or that a milestone gain equals cure.

Acknowledging the Evidence Gaps That Clinicians Should Discuss Openly With Families

The intravenous infant program relied largely on small single-arm trials and natural-history comparison. Presymptomatic outcomes are striking but come from very small selected cohorts. The current long-term cohort is encouraging but confounded by subsequent treatment. STEER provides randomized evidence for intrathecal therapy in a defined pediatric population, yet the average effect was modest, secondary endpoints did not pass multiplicity control, and adult efficacy was extrapolated. Real-world cohorts broaden generalizability but add selection, treatment, and follow-up heterogeneity.[4,5,6,7,8,9,10,11,12,13,14]

These limitations do not negate benefit. They define the level of certainty that should accompany counseling. Clinicians can reasonably say that early gene transfer can transform prognosis, that later treatment can improve or stabilize function in some patients, and that serious toxicity is manageable only with disciplined surveillance. They should not promise normal development, independence, a permanent response from one dose alone, freedom from supportive care, or superiority over every other disease-modifying option.

 

References

1. U.S. Food and Drug Administration. ZOLGENSMA (onasemnogene abeparvovec-xioi) prescribing information. Revised June 2026. FDA source
2. U.S. Food and Drug Administration. ITVISMA (onasemnogene abeparvovec-brve) prescribing information and Medication Guide. Revised June 2026. FDA source
3. Schroth MK, Deans J, Bharucha Goebel DX, et al. Spinal Muscular Atrophy Update in Best Practices: Recommendations for Treatment Considerations. Neurol Clin Pract. 2025;15(1):e200374. DOI | PubMed | PMC
4. Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1713-1722. DOI | PubMed
5. Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284-293. DOI | PubMed
6. Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(10):832-841. DOI | PubMed
7. Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med. 2022;28(7):1381-1389. DOI | PubMed
8. Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med. 2022;28(7):1390-1397. DOI | PubMed
9. Waldrop MA, Bernardo Escudero R, Yang L, et al. Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study. EClinicalMedicine. 2026;94:103867. DOI | PubMed | PMC
10. Proud CM, Vu DC, Wilmshurst JM, et al. Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial. Nat Med. 2026;32(2):481-487. DOI | PubMed | PMC
11. U.S. Food and Drug Administration. Summary Basis for Regulatory Action: ITVISMA (onasemnogene abeparvovec-brve). November 24, 2025. FDA source
12. Kwon JM, Munell F, Le Goff L, et al. Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial. Nat Med. 2026;32(2):488-493. DOI | PubMed
13. Weiss C, Ziegler A, Becker LL, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022;6(1):17-27. DOI | PubMed
14. Desguerre I, Barrois R, Audic F, et al. Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment. Orphanet J Rare Dis. 2024;19:344. DOI | PubMed | PMC
15. Proud CM, Kichula EA, Matesanz SE, et al. Onasemnogene abeparvovec gene therapy for treatment of patients with spinal muscular atrophy: Updated real-world practical considerations. J Neuromuscul Dis. 2026;13(4):587-601. DOI | PubMed
16. Chand D, Mohr F, McMillan H, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021;74(3):560-566. DOI | PubMed
17. Day JW, Mendell JR, Mercuri E, et al. Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. Drug Saf. 2021;44(10):1109-1119. DOI | PubMed
18. Kichula EA, Proud CM, Farrar MA, et al. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve. 2021;64(4):413-427. DOI | PubMed | PMC
19. Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103-115. DOI | PubMed
20. Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197-207. DOI | PubMed